Company news

Scancell Holdings PLC news in 2026

Scancell Holdings PLC's news releases, calls and decks from 2026, newest first.

View company

Notice of AGM

October 23, 2026

Result of General Meeting

October 20, 2026

Issue of Equity, Director Dealing & Voting Rights

October 15, 2026

Preliminary Results

October 9, 2026

Notice of GM

October 2, 2026

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

September 24, 2026

Scancell to Present at the H.C. Wainwright Sept 26

September 3, 2026

iSCIB1+ MHRA CTA Approval for Ph3 trial

August 19, 2026

Extension of Option Exercise Period

July 31, 2026

Correction: Merger and Financing

July 24, 2026

Merger and Financing

July 23, 2026

Scancell: Response to Press Speculation

June 26, 2026

Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study

April 28, 2026

Scancell announces CFO transition

April 2, 2026

Interim Results for the six months ended 31 October 2025

January 29, 2026

Half-year Financial Report

January 29, 2026

Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma

January 26, 2026

FDA clearance of IND application for iSCIB1+

January 26, 2026

Notice of Results

January 22, 2026

Decks in 2026